CompletedNCT00535574
Bexarotene added to antipsychotic treatment for schizophrenia
About this title
Read the official source — NCT00535574Medication studyAges 18–60Israel
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- Beersheba and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 90
- Sponsor
- Beersheva Mental Health Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Israel
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00535574
- Official title
Show the full official title
Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia: a 6-week, Randomized, Double-blind Placebo-controlled Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Beersheba · Bat Yam · Hadera
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Beersheva Mental Health Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Bexarotene (Targretin LGD1069) and bexarotene.
Who was this study for?
Listed age limits: 18 years to 60 years.
